Bicara Therapeutics' lead candidate, ficerafusp alfa, targets EGFR and TGF-beta in tumors, showing promise in hard-to-treat cancers like Head and Neck Squamous Cell Carcinoma. Bicara's financial ...
Bicara Therapeutics Inc., led by Dr. Claire Mazumdar, recently IPO'd with a promising bifunctional antibody, ficerafusp alfa, targeting head and neck cancer. Ficerafusp alfa shows impressive interim ...
IO Biotech presents preclinical data supporting dual-antigen and TGF-β-targeted vaccines for enhancing anti-tumor immunity at AACR 2025. IO Biotech presented new preclinical data at the AACR Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback